Compare CFFI & CCCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CFFI | CCCC |
|---|---|---|
| Founded | 1927 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 218.0M | 240.3M |
| IPO Year | 1998 | 2020 |
| Metric | CFFI | CCCC |
|---|---|---|
| Price | $71.19 | $1.92 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $7.25 |
| AVG Volume (30 Days) | 6.2K | ★ 1.9M |
| Earning Date | 01-27-2026 | 11-06-2025 |
| Dividend Yield | ★ 2.53% | N/A |
| EPS Growth | ★ 43.03 | N/A |
| EPS | ★ 8.09 | N/A |
| Revenue | ★ $125,432,000.00 | $30,108,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $8.97 | ★ N/A |
| Revenue Growth | ★ 9.28 | N/A |
| 52 Week Low | $53.14 | $1.09 |
| 52 Week High | $89.90 | $4.26 |
| Indicator | CFFI | CCCC |
|---|---|---|
| Relative Strength Index (RSI) | 51.85 | 34.02 |
| Support Level | $67.83 | $1.93 |
| Resistance Level | $73.16 | $2.13 |
| Average True Range (ATR) | 2.26 | 0.13 |
| MACD | -0.43 | -0.03 |
| Stochastic Oscillator | 41.06 | 2.53 |
C&F Financial Corp is an American bank holding company. The company through its subsidiaries offers banking and related financial services to both individuals and businesses. It operates in three business activities: Community Banking, Mortgage Banking, and Consumer Finance. It mainly provides a range of lending activities, which include residential mortgage loans, commercial real estate loans, non-prime automobile lending, land acquisition, and development loans, and consumer loans. The company generates maximum of its revenue from the Community Banking segment.
C4 Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patients' lives. The Company is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. Its degrader medicines are designed to harness the body's natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, and drug undruggable targets and improve patient outcomes. Its pipeline is Cemsidomide, CFT1946, and CFT8919.